OpenAlex
PricingAboutJobs
Log inGet started
Work

How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes? Completed and Ongoing Mechanistic Trials

HTML

Year: 2020
Type: review
Source: Arteriosclerosis Thrombosis and Vascular Biology
DOI: 10.1161/atvbaha.119.311904
Authors: Matthew M.Y. Lee, Mark C. Petrie, John J.V. McMurray, Naveed Sattar
Institution: University of Glasgow
Language: English

Topic: Diabetes Treatment and Management
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: SGLT2 inhibitors, GLP-1 receptor agonists, cardiovascular outcomes, renal outcomes, mechanism of action, type 2 diabetes, type 1 diabetes, heart failure, coronary artery disease, left ventricular mass, myocardial energetics, infarct size, liver fat, weight loss, blood pressure reduction
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W3004668878
FWCI: 1.243
Cites: 66
Cited by: 62
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security